Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine

Clinical Infectious Diseases

Volumn 20, Issue 2, 1995, Pages 316-319

  Watson, B ^a,b   Boardman, C ^a,b   Laufer, D ^a,b   Piercy, S ^a,b   Tustin, N ^a,b   Olaleye, D ^a,b   Cnaan, A ^a,b   Starr, S E ^a,b  

^a the Joseph Stokes Jr Research Institute   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CHILD; DOSE RESPONSE; HUMAN; HUMORAL IMMUNITY; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 3, HUMAN; HUMAN; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; INFANT; LYMPHOCYTE ACTIVATION; MALE; SUPPORT, NON-U.S. GOV'T; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0028891001     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.2.316     Document Type: Article

References (13)

1. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271:375-81.
2. Preblud SR. Varicella: complications and costs. Pediatrics 1986; 78:728-35.
3. Weibel RE, Neff BJ, Kuter BJ. et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310:1409-15.
4. Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. JPediatr 1982; 100:886-93.
5. Arbeter AM, Starr SE, Preblud SR. et al. Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies. Am J Dis Child 1984; 138:434-8.
6. White CJ., Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials. 1987 to 1989. Pediatrics 1991;87:604-10.
7. Watson BM, Piercy SA., Plotkin SA., Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
8. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19-23.
9. Diaz PS, Smith S, Hunter E, Arvin AM. Immunity to whole varicella- zoster virus antigen and glycoproteins 1 and pi70: relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis 1988:158:1245-52.
10. Watson BM, Keller PM, Ellis RW, Starr SE. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 1990: 162:794-9.
11. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992; 166(suppl I):S350-41.
12. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis 1994; 169:197-9.
13. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985:75:667-71.